Arnold M, Singh D, Laversanne M, Vignat J, Vaccarella S, Meheus F, et al. Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040. JAMA Dermatol. 2022;158(5):495–503. https://doi.org/10.1001/jamadermatol.2022.0160.

Article  PubMed  PubMed Central  Google Scholar 

Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. Cancer statistics, 2026. CA Cancer J Clin. 2026;76(1):e70043. https://doi.org/10.3322/caac.70043.

Article  PubMed  PubMed Central  Google Scholar 

Curti BD, Faries MB. Recent advances in the treatment of melanoma. N Engl J Med. 2021;384(23):2229–40. https://doi.org/10.1056/NEJMra2034861.

Article  CAS  PubMed  Google Scholar 

Gebhardt C, Lichtenberger R, Utikal J. Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients. J Dtsch Dermatol Ges. 2016;14(2):158–64. https://doi.org/10.1111/ddg.12727.

Article  PubMed  Google Scholar 

Ertekin S, Podlipnik S, Ribero S, Molina R, Rios J, Carrera C, et al. Monthly changes in serum levels of S100B protein as a predictor of metastasis development in high-risk melanoma patients. J Eur Acad Dermatol Venereol. 2020;34(7):1482–8. https://doi.org/10.1111/jdv.16212.

Article  CAS  PubMed  Google Scholar 

Posch C. A fresh perspective on an established marker: S100B-dynamics for early detection of melanoma recurrence. J Eur Acad Dermatol Venereol. 2020;34(7):1386–1386. https://doi.org/10.1111/jdv.16731.

Article  CAS  PubMed  Google Scholar 

Pantel K, Alix-Panabières C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010;16(9):398–406. https://doi.org/10.1016/j.molmed.2010.07.001.

Article  PubMed  Google Scholar 

Alix-Panabières C, Pantel K. Liquid biopsy: from discovery to clinical application. Cancer Discov. 2021;11(4):858–73. https://doi.org/10.1158/2159-8290.CD-20-1311.

Article  PubMed  Google Scholar 

Moser T, Kühberger S, Lazzeri I, Vlachos G, Heitzer E. Bridging biological cfDNA features and machine learning approaches. Trends Genet. 2023;39(4):285–307. https://doi.org/10.1016/j.tig.2023.01.004.

Article  CAS  PubMed  Google Scholar 

Genta S, Araujo DV, Hueniken K, Pipinikas C, Ventura R, Rojas P, et al. Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients. ESMO Open. 2024;9(11):103978. https://doi.org/10.1016/j.esmoop.2024.103978.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yazaki S, Tokura M, Aiba H, Kojima Y, Shiraishi K. Clinical applications of cell-free DNA-based liquid biopsy analysis. Transl Oncol. 2025;6(61):102519. https://doi.org/10.1016/j.tranon.2025.102519.

Article  CAS  Google Scholar 

Ma VT, Zhou AY, Forati A, Hollnagel F, Patel JD, Burkey C, et al. Multi-institutional study evaluating the role of early circulating tumor DNA dynamics during treatment with immune checkpoint inhibitors in patients with advanced-stage melanoma. JCO Precis Oncol. 2026;10(2):e2500254. https://doi.org/10.1200/PO-25-00254.

Article  PubMed  PubMed Central  Google Scholar 

Herbreteau G, Vallée A, Knol AC, Théoleyre S, Quéreux G, Varey E, et al. Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy. Oncotarget. 2018;9(38):25265–76. https://doi.org/10.18632/oncotarget.25404.

Article  PubMed  PubMed Central  Google Scholar 

Marchisio S, Ricci AA, Roccuzzo G, Bongiovanni E, Ortolan E, Bertero L, et al. Monitoring circulating tumor DNA liquid biopsy in stage III BRAF-mutant melanoma patients undergoing adjuvant treatment. J Transl Med. 2024;28(22):1074. https://doi.org/10.1186/s12967-024-05783-7.

Article  CAS  Google Scholar 

Steimle AK, Cho SY, Menon N, Jeraj R, Birbrair A, Albertini MR, et al. ctDNA dynamics identifies pseudoprogression in a metastatic melanoma patient treated with nivolumab/relatlimab. J Immunother. 2025;48(8):325–8. https://doi.org/10.1097/CJI.0000000000000569.

Article  CAS  PubMed  Google Scholar 

Al-Showbaki L, Wilson B, Tamimi F, Molto C, Mittal A, Cescon DW, et al. Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review. J Immunother Cancer. 2023;11(2):e005854. https://doi.org/10.1136/jitc-2022-005854.

Article  PubMed  PubMed Central  Google Scholar 

De Simoni E, Spagnolo F, Gandini S, Gaeta A, Rizzetto G, Molinelli E, et al. Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma. Cancer Treat Rev. 2024;129:102788. https://doi.org/10.1016/j.ctrv.2024.102788.

Article  CAS  PubMed  Google Scholar 

Heidrich I, Deitert B, Werner S, Pantel K. Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors. Cancer Metastasis Rev. 2023;42(1):161–82. https://doi.org/10.1007/s10555-022-10075-x.

Article  PubMed  PubMed Central  Google Scholar 

Gebhardt C, Keller L, Heidrich I, Koett J, Geidel G, Abbott C, et al. Association of ultra-sensitive ctDNA assay to identify actionable variants and response to immune checkpoint inhibitor (ICI) therapy in metastatic melanoma. JCO. 2023;41(16_suppl):9562–9562. https://doi.org/10.1200/JCO.2023.41.16_suppl.9562

Nishimura T, Kakiuchi N, Yoshida K, Sakurai T, Kataoka TR, Kondoh E, et al. Evolutionary histories of breast cancer and related clones. Nature. 2023;620(7974):607–14. https://doi.org/10.1038/s41586-023-06333-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen K, Yang F, Shen H, Wang C, Li X, Chervova O, et al. Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer. Cancer Cell. 2023;41(10):1749-1762.e6. https://doi.org/10.1016/j.ccell.2023.08.010.

Article  CAS  PubMed  Google Scholar 

Brunsgaard EK, Bowles TL, Asare EA, Grossmann K, Boucher KM, Grossmann A, et al. Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma. Melanoma Res. 2023;33(3):184–91. https://doi.org/10.1097/CMR.0000000000000892.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carlino MS, Khattak A, Weber JS, Meniawy T, Sullivan RJ, Taylor MH, et al. Minimal residual disease by circulating tumor DNA as a biomarker of recurrence free survival in resected high-risk melanoma patients treated with mRNA-4157/V940, a personalized cancer vaccine, and pembrolizumab. JCO. 2023;41(17_suppl):LBA9515–LBA9515. https://doi.org/10.1200/JCO.2023.41.17_suppl.LBA9515.

Article  Google Scholar 

Widman AJ, Shah M, Frydendahl A, Halmos D, Khamnei CC, Øgaard N, et al. Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment. Nat Med. 2024;30(6):1655–66. https://doi.org/10.1038/s41591-024-03040-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haselmann V, Gebhardt C, Brechtel I, Duda A, Czerwinski C, Sucker A, et al. Liquid profiling of circulating tumor DNA in plasma of melanoma patients for companion diagnostics and monitoring of BRAF inhibitor therapy. Clin Chem. 2018;64(5):830–42. https://doi.org/10.1373/clinchem.2017.281543.

Article  CAS  PubMed  Google Scholar 

Heidrich I, Rautmann C, Ly C, Khatri R, Kött J, Geidel G, et al. In-depth assessment of BRAF, NRAS, KRAS, EGFR, and PIK3CA mutations on cell-free DNA in the blood of melanoma patients receiving immune checkpoint inhibition. J Exp Clin Cancer Res. 2025;44(1):202. https://doi.org/10.1186/s13046-025-03457-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kisistók J, Christensen DS, Rasmussen MH, Duval L, Aggerholm-Pedersen N, Luczak AA, et al. Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel. Melanoma Res. 2023;33(5):364–74. https://doi.org/10.1097/CMR.0000000000000903.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu L, Hou S, Zhu A, Yan B, Li L, Song D. The prognostic value of circulating tumor DNA in malignant melanoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Immunol. 2025;15:1520441. https://doi.org/10.3389/fimmu.2024.1520441.

Article  CAS